Every comparison on PeptidesView follows the same method, so that two pages can be read the same way.
1. Start with the question people actually ask
We pick comparisons that readers search for, then define what “better” could mean for each goal. A peptide can have stronger evidence for one outcome and none for another, so we compare outcome by outcome, not overall.
2. Count the evidence, outcome by outcome
For each outcome we record the strongest type of evidence that exists for each peptide:
- Regulatory approval for that use
- Randomised controlled trials in people
- Other human data (small, open-label or observational studies, case reports)
- Animal studies
- Laboratory studies (cells or tissue)
The “at a glance” table on every comparison shows these side by side, with the number of human studies where there are any. When the answer is “no human studies”, we say so.
3. Report status and risk with the same weight as effects
Each comparison includes FDA and anti-doping (WADA) status, the date that status was checked, and known or suspected risks. A comparison that shows benefits without risks is incomplete.
4. No dosing instructions
We do not publish dosing protocols, dose calculators or preparation and injection instructions. Where doses matter to understand a study, we report the dose used in that study, in that species, with the source.
5. Sources
We use peer-reviewed research (PubMed / PubMed Central), trial registries (ClinicalTrials.gov) and regulators (FDA, EMA, MHRA, TGA, WADA). Vendor pages, forums and social media are never used as evidence.
How pages are produced and updated
Drafts are prepared with AI assistance from the sources cited on each page, then pass automated checks that match every citation and number to its source; unsupported claims are removed. The PeptidesView Editorial Team is responsible for all published content. Pages show their publication and update dates, and comparisons are revised when new studies or regulatory decisions change the picture. Report errors through the contact page.